MRK vs RARE
Merck & Co. vs Ultragenyx Pharmaceutical Inc. — AI-powered side-by-side comparison
VS
RARE
Ultragenyx Pharmaceutical Inc.
56
Watch
| Metric | MRK | RARE |
|---|
| AI Score |
70
|
56
|
| Price |
$130.34
|
$26.96
|
| P/E Ratio |
103.53×
|
-4.62×
|
| ROE |
34.7%
|
718.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
83.1%
|
| Debt / Equity |
1.29×
|
-4.13×
|
| Dividend Yield |
2.6%
|
0.0%
|
| RSI (14) |
64.5
|
54.3
|
| Beta |
0.207
|
0.313
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MRK versus RARE.
MRK leads by 14 points.
MRK scores 70/100 (Buy) versus RARE at 56/100 (Watch).
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
RARE Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 27.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
- Bollinger bandwidth of 27.5% signals elevated volatility — Risk